Pfizer’s COX-2 Scripts Take More Hits From Kaiser
This article was originally published in The Tan Sheet
Executive Summary
A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors
You may also be interested in...
NSAIDs Vs. COX-2s: Study Prompts Labeling Review By FDA On Merck’s Vioxx
OTC NSAID manufacturers may have been handed a significant marketing opportunity against COX-2s in the form of results from a retrospective study indicating the Rx pain relievers carry a higher risk of a serious cardiac event compared to their nonprescription counterparts
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands